Viewing nowPMS Pregabalin Capsule 75mg
Pregabalin 75mg
Hard capsule · Prescription medication
PharmaScience Korea Co., Ltd.

MFDS item code 201605665 · Approved 2016.09.27 · Insurance code 627600150
Treatment of neuropathic pain, adjunctive treatment of epilepsy (partial-onset seizures), and treatment of fibromyalgia
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in patients with epilepsy, with or without secondary generalized symptoms. Additionally, it helps alleviate symptoms of fibromyalgia. It is effectively used for various neurological disorders and pain symptoms.
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined by renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration regimen. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12-17 years because there are insufficient safety and efficacy data.
This medicine may increase the risk of suicidal thoughts or behavior, so any mood changes or symptoms of depression during treatment should be reported to healthcare professionals immediately. Patients allergic to any components of this medication or those with certain genetic disorders should not take it. Diabetic patients should be cautious about blood sugar management as weight gain may hinder blood sugar control. If symptoms of angioedema occur, stop taking this medication immediately and consult a hospital. Elderly patients may experience increased dizziness and drowsiness when taking this medication, so caution is necessary to prevent falls. Visual disturbances or changes in eyesight may occur; consult healthcare professionals if any unusual symptoms arise. Abruptly stopping this medication may lead to withdrawal symptoms such as insomnia, anxiety, and headaches, thus it should be discontinued gradually according to a doctor's instructions. There is a risk of drug abuse, so patients with a history of substance abuse should be particularly cautious and monitored for misuse or dependence symptoms. Patients with reduced kidney function may require dosage adjustments. Patients with heart disease or congestive heart failure should be cautious when taking this medication. This medication has central nervous system depressant effects, so caution is necessary to avoid respiratory depression when taken with opioids or similar analgesics. Pregnant women should avoid this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. Women who are breastfeeding should consult a doctor about whether to discontinue breastfeeding, as this medication may be transmitted through breast milk. Activities requiring concentration, such as driving or operating machinery, should be avoided until dizziness or drowsiness has completely subsided. In case of overdose, symptoms such as confusion, drowsiness, depression, and seizures may occur, and treatment such as hemodialysis may be required if necessary. Keep out of reach of children, and avoid transferring to other containers. If serious allergic reactions such as skin rash, fever, or difficulty breathing occur during the use of this medication, stop taking it immediately and contact healthcare professionals.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is recommended to maintain a storage temperature between 15°C and 30°C. This way, the efficacy and safety of the medication can be preserved for a long time.
A reddish-brown opaque capsule with a white or pale yellow powder inside.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
PharmaScience Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.